Molecular mechanisms and therapeutic strategies for small‑cell lung cancer transformation after TKI therapy in EGFR‑mutated lung adenocarcinoma (Review)

Abstract excerpt

Lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations is a common subtype of non-small cell lung cancer (NSCLC). Although it responds well to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), acquired resistance to EGFR-TKIs inevitably occurs, which limits the use of the EGFR-TKIs. One resistance mechanism is small-cell transformation, which refers to the histological switch of EGFR-mutant lung...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations
• Share to Neuroendocrine Tumor Research Advances